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Highlights 
 
What is already known about the topic? 
- EQ5D-5L is a relatively new development for measuring health related quality of life and health utility. 
It aims to improve sensitivity and reduce ceiling effects compared to EQ5D-3L. But little is known 
about how the two instruments relate to each other.   
 
What does the paper add to existing knowledge? 
- The paper provides a means of linking 3L to 5L, and vice versa, for use in situations where only one 
instrument has been completed by respondents. It shows that moving from 3L to 5L is not a simple 
uniform realignment of the response levels. Improvements in quality of life are valued less using 5L 
than with 3L. 
 
What insights does the paper provide for informing health care-related decision making? (optional) 
- Results from studies that use different versions of EQ5D cannot be directly compared. There is no 
simple proportional adjustment that can be made to reconcile these differences.  
   
ABSTRACT 245 words (250 words max) 
Objectives 
To model the relationship between EQ-5D-3L and EQ-5D-5L and examine how differences impact on cost-
effectiveness in case studies. 
Methods 
We used two datasets that included both EQ-5D-3L and EQ-5D-3L from the same respondents. The EuroQoL 
dataset (n=3551) included patients with different diseases and a healthy cohort. The NDB included patients with 
rheumatoid disease (n=5205). We estimated a system of ordinal regressions in each dataset using copula 
models, to link responses to the 3L instrument to 5L and its tariff, and vice versa. Results were applied to nine 
cost-effectiveness studies.  
Results 
Best-fitting models differed between EuroQoL and NDB datasets in terms of the explanatory variables, copulas 
and coefficients. In both cases the coefficients of the covariates and latent factor between -3L and -5L were 
significantly different, indicating that the two instruments are not a uniform realignment of the response levels 
for most dimensions. In the case studies, moving from 3L to 5L caused a decrease of up to 87% in incremental 
QALYs gained from effective technologies in almost all cases. ICERs increased, often substantially. 
Technologies with a significant mortality gain saw increases in incremental QALYs.  
Conclusion 
5L shifts mean utility scores up the utility scale towards full health and compresses them into a smaller range, 
compared to -3L. Improvements in quality of life are valued less using 5L than with 3L. 
3L and 5L produce substantially different estimates of cost effectiveness. There is no simple proportional 
adjustment that can be made to reconcile these differences.  
 
 
  
INTRODUCTION 
The EQ-5D comprises a descriptive system of health-related quality of life and associated tariffs or “utility” 
scores. The descriptive system covers five dimensions of health: mobility, ability to self-care, ability to 
undertake usual activities, pain and discomfort, and anxiety and depression. The original version of EQ-5D 
allows respondents to indicate the degree of impairment on each dimension according to three levels (no 
problems, some problems, extreme problems). This is the EQ-5D-3L. A new version of the instrument, EQ-5D-
5L, includes five levels of severity for each dimension (no problems, slight problems, moderate problems, 
severe problems, and extreme problems) with the intention of improving the instrument’s sensitivity and 
reducing ceiling effects1. Tariffs for this 5L version are now available for England, Canada, Japan, Uruguay, the 
Netherlands and Korea.  
 
EQ-5D is one of the most widely used instruments underpinning economic evaluations conducted in terms of 
cost-per Quality Adjusted Life Year (QALY). It is therefore essential to understand the implications of using the 
new 5L version of the instrument compared to the 3L version. This paper provides information on how the two 
versions of EQ-5D relate to each other, using the UK tariffs. This is done by utilising two reference datasets 
where patients filled in both 3L and 5L instruments. We estimate the joint distribution of responses to the two 
instruments. This model is then used in 9 cost-effectiveness studies to compare results when using directly 
observed 3L values with estimated 5L results.  
 
METHODS 
Data 
We used two reference datasets.  
 
The first was provided by the EuroQoL group (the EQG data). Conducted between August 2009 and September 
2010, the EuroQoL Group coordinated and partly funded a data collection study. Its main aim was to collect 
data on both versions of EQ-5D, the 3L and 5L, to compare them in terms of their measurement properties and 
to generate an interim value set for EQ-5D-5L using a mapping (or cross-walk) approach. The questionnaire 
introduced the 5 level version of EQ-5D first, followed by a few background questions (age, gender, education, 
etc), then the 3 level version of EQ-5D, the EQ-5D visual analogue scale, a set of five dimension specific rating 
scales and finally the WHO (five) Well-Being index. The study was carried out in 6 countries: Denmark, 
England, Italy, the Netherlands, Poland and Scotland and included eight broad patient groups (cardiovascular 
disease, respiratory disease, depression, diabetes, liver disease, personality disorders, arthritis, and stroke) and a 
student cohort (healthy population). Each country used the official EQ-5D language versions and data was 
mainly collected through specialist hospitals/centres and patient recruitment agencies. All countries used paper 
and pencil questionnaires, apart from England which used an online version. In all countries, except Italy, a 
screening protocol was used to ensure a wide range of severity across all the EQ-5D-5L and EQ-5D-3L 
dimensions. 
 
The NDB is a register of patients with rheumatoid disease, primarily recruited by referral from US and Canadian 
rheumatologists. Information supplied by participants is validated by direct reference to records held by 
hospitals and physicians (A minority of cases come by self-referral, with medical details obtained by NDB in 
the same way). Full details of the recruitment process are given by Wolfe and Michaud (2011)2 . The EQ-5D 
responses and other patient-supplied data are collected by various means, primarily postal and web-based 
questionnaires completed directly by patients. Data collection began in 1998 and continues to the present, in 
waves administered in January and July of each year. In 2011, there was a switch from 3-level to the 5-level 
version of EQ-5D and both versions were collected in parallel during the January 2011 wave. The NDB 
questionnaire is 27 pages long and it includes many general as well as RA specific questions. EQ-5D-5L and 
EQ-5D-3L are on pages 11 and 22 of the questionnaire respectively. This wave is used to estimate the model. 
 
Statistical analysis 
The aim is to estimate the relationship between the two instruments. Hernandez and Pudney have previously 
developed a flexible model which allows analysis of the joint responses to EQ-5D-3L and EQ-5D-5L3. The 
model is a system of ordinal regressions estimated jointly, incorporating a flexible copula mixture residual 
distribution. It is a type of response mapping model with all equations for the five health domains and two 
versions of the EQ-5D instrument estimated jointly. Thus, there are 10 ordinal regressions corresponding to the 
five dimensions of EQ-5D-5L and the five dimensions of EQ-5D-3L. Following the natural pairing of the 
dimensions in the two versions of EQ-5D, the 10 regressions are arranged in five groups. Each group 
corresponds to one EQ-5D dimension and contains an ordinal regression for EQ-5D-5L and another for EQ-5D-
3L.  
 
To capture the dependence between the two regressions in each dimension we use a copula representation. 
Copulas are very useful as they can generate a number of dependence structures. Different copulas were 
assessed in the analysis.  
 
To complete the model, the five bivariate groups of regressions are linked by a latent factor which represents 
background response behaviour. Some respondents may have a tendency to give pessimistic assessments, while 
others tend to make light of their health problems. The common latent factor varying across individuals 
represents this type of heterogeneity, and has the effect of inducing correlation between all responses from the 
same individual. 
 
Statistical models like this are sensitive to the distributional assumptions, the usual one being normality. 
Misspecification of the joint residual distribution may lead to significant bias in the estimated coefficients of the 
covariates, in addition to giving a distorted picture of the dependence. For this reason, mixture distributions are 
used to allow for non-normality in the residuals and the latent factor representing the individual’s response 
behaviour. 
 
Summing up, the multi-equation model described above allows for the discrete nature of responses to EQ-5D 
and uses a highly flexible mixture-copula specification of the underlying latent model. Importantly, the model 
does not impose the assumption that responses in the five dimensions of EQ-5D are statistically independent. 
For the purposes of this study, the advantage of a response mapping type model is that it allows a) the 
consistency of the responses to the two descriptive systems to be investigated and b) the implied differences in 
the utility values to be analysed. It, therefore, also enables investigation of the impact on economic evaluation 
decisions of moving from the 3- level version of EQ-5D to the new 5- level version. 
 
Cost effectiveness case studies 
We used the copula mapping models in nine cost-effectiveness case studies.  
 
All were economic evaluations based on individual patient level data using EQ-5D-3L. We made a pragmatic 
decision in selecting case-studies. We sought collaborators who had previously completed suitable studies using 
the 3L instrument and who were willing and able to replicate their study substituting predicted utility scores for 
5L using a bespoke Stata command.  Included studies were: 
1) CARDERA - The Combination of Anti-Rheumatic Drugs in Early Rheumatoid Arthritis (CARDERA) 
trial was a double-blind, factorial designed, placebo-controlled randomized trial which compared the 
benefits of adding cyclosporine, high-dose step-down prednisolone or both to methotrexate 
monotherapy4.  
2) CACTUS - The Cost-effectiveness of Aphasia Computer Treatment Compared to Usual Stimulation 
(CACTUS) pilot randomized controlled trial tested the feasibility of comparing self-managed computer 
therapy combined with usual stimulation (such as participation in normal language stimulation 
activities and support groups) to usual stimulation alone in people with aphasia5. 
3) RAIN - The Risk Adjustment in Neurocritical care (RAIN) trial compared a) Management in a 
dedicated neurocritical care unit versus a combined neuro/general critical care unit, and; b) ‘Early’ 
transfer to a neuroscience centre versus ‘no or late’ transfer, for patients who initially present at a non-
neuroscience centre and do not require urgent neurosurgery, for patients with acute traumatic brain 
injury. 
4) IMPROVE - The Immediate Management of Patients with Rupture: Open Versus Endovascular Repair 
(IMPROVE) trial compared either endovascular repair or open repair of ruptured abdominal aortic 
aneurysm (AAA)6 
5) COUGAR-02 - The COUGAR-02 randomised, controlled, open-labelled trial compared docetaxel 
chemotherapy plus active symptom control and active symptom control only in patients in the UK with 
advanced adenocarcinoma of the oesophagus, oesophagogastric junction, or stomach7 . 
6) ARCTIC - The Attenuated dose Rituximab with ChemoTherapy in CLL (ARCTIC) study was a multi-
centre, randomised, controlled, open, phase IIB non-inferiority trial conducted in previously untreated 
patients with Chronic Lymphocytic Leukaemia (CLL)8,9. It compared fludarabine, cyclophosphamide 
and rituximab (FCR), which is considered conventional frontline therapy, with fludarabine, 
cyclophosphamide, mitoxantrone and low dose rituximab (FCM-miniR). 
7) SHARPISH - The Self-Help and Relapse Prevention in Smoking for Health (SHARPISH) trial10 sought 
to estimate the effectiveness and cost-effectiveness of self-help booklets versus a single leaflet to 
prevent smoking relapse in people who had stopped smoking for four weeks.  
8) WRAP – the Weight-Reduction Activity Programme (WRAP)11 was a multi-centre, non-blinded, three-
arm parallel groups randomised controlled trial of two commercial weight loss programmes, compared 
to a brief intervention in overweight adults. 
9) CvLPRIT - The CvLPRIT (Complete- compared to Lesion-Only Revascularisation For Myocardial 
Infarction) trial12 randomised patients presenting with ST-segment elevation Myocardial Infarction 
(STEMI) with bystander stenosis to an infarct-only strategy (only treat the blocked artery which caused 
the heart attack) vs. complete revascularisation (treat the blocked artery and also treat any narrowed 
arteries which may cause heart attacks in future). 
 
We use the UK/English value sets for the 3L and 5L versions of EQ-5D13,14. 
RESULTS 
Datasets  
After exclusion of missing values, there were final estimation samples of 3551 and 5205 respondents in the 
EQG and NDB datasets respectively. The EQG sample is younger and contains more males than the NDB (see 
Table 1). 
 
Figure 1 shows histograms of the response distributions for each dimension of the 3L and 5L versions of EQ-5D 
in both datasets. There are differences both across the dimensions and between the datasets. Four distinct 
distributional shapes can be identified: 
i. Decreasing profile with a dominant mode at the first category. 
This distributional shape can be seen in the self-care dimension of both EQ-5D-3L and EQ-5D-5L and in the 
mobility and usual activities dimension of EQ-5D-5L in the EQG dataset and on the self-care and 
anxiety/depression of both versions of EQ-5D in the NDB dataset. 
ii. Decreasing profile with a heavier central section. 
In the EQG dataset, the pattern can be seen in the mobility dimension (EQ-5D-3L) and, pain/discomfort and 
anxiety/depression (EQ-5D-5L). In the NDB dataset, the mobility and usual activities dimensions for both 
versions of EQ-5D exhibit this shape 
iii. A strong mode in the centre of the distribution. 
This shape can be found in the pain/discomfort dimension in EQ-5D-3L in the EQG dataset and in both versions 
of EQ-5D in the NDB dataset. 
iv. A mode in the centre of the distribution and an almost as large first category. 
This distributional shape is similar to shape (ii) in that they both exhibit a decreasing profile, but shape (iv) has 
less central concentration. This shape can only be found in the EQG dataset in the usual activities and 
anxiety/depression dimensions of EQ-5D-3L. 
 
In the NDB dataset, both versions of EQ-5D display the same pattern within each dimension but different 
shapes across dimensions: shape (i) in both the self-care and anxiety/depression dimensions, shape (ii) in the 
mobility and usual activities dimension and shape (iii) in the pain/discomfort dimension. In contrast, in the EQG 
dataset only the self-care dimension shows the same shape of distribution in both EQ-5D-3L and EQ-5D-5L. 
Within the EQG dataset, the distributional shapes for all dimensions of EQ-5D-5L are similar, displaying a 
decreasing profile corresponding to either shape (i) or (ii). The EQ-5D-3L distributions in the EQG dataset 
exhibit all four distributional shapes and appear more different across dimensions than in the 5 level version. 
 
  
Figure 2 shows kernel estimates of the distributions of utility scores in both datasets. EQ-5D-3L in both datasets 
exhibits the typical characteristics documented in the literature: a large mass of observations at 1 (full health), a 
gap of no observations between full health and the next feasible value (0.883) and a multimodal distribution.  In 
both datasets, the distributions are smoother for EQ-5D-5L, especially towards the top of the distribution. The 
number of individuals in full health is reduced by using EQ-5D-5L and the mode at the bottom of the 
distribution around the value of zero in the EQ-5D-3L distribution disappears in the distribution of EQ-5D-5L. 
The mean and median of EQ-5D-5L are higher than the corresponding mean and median of EQ-5D-3L in both 
datasets (see Table 1). The range of EQ-5D-5L is smaller as the worst state has a utility score of -0.281 
compared to -0.594 of EQ-5D-3L. 
 
Statistical model results 
Five different copulas, Gaussian, Clayton, Frank, Gumbel and Joe, were assessed in the analysis. The initial 
specification had gender, age and the square of age as covariates. The square of age was significant when the 
model was estimated with EQG data, but grossly insignificant when estimated with NDB data. The preferred 
specification for the EQG dataset has age, age squared and gender as covariates in all ten ordinal regressions 
whereas the model for the NDB dataset excludes the square of age. 
 
Table 2 summarizes the results for the two datasets. There are several differences between the models from the 
two datasets. The best fitting model in the EQG dataset chooses the same copula, Frank, in all dimensions of 
EQ-5D.  In contrast, the best fitting model in the NDB dataset selects a Gaussian copula for the mobility, usual 
activities and pain/discomfort dimensions, a Clayton copula for the self-care dimension and a Frank copula for 
the anxiety/depression dimension.  Therefore, in the EQG dataset the patterns of residual dependence between 
the 3- and 5- level versions of EQ-5D are similar across all dimensions indicating symmetric dependence and 
weak dependence on the tails. In the NDB dataset, a Frank copula was also selected for the anxiety/depression 
dimension and the parameter of dependence was very similar that estimated in the EQG dataset. In contrast, the 
Gaussian copula in the mobility, usual activities and pain/discomfort dimensions indicate symmetric dependence 
as well but stronger dependence on the tails of the distribution than the Frank copula selected in the EQG 
dataset. The copula chosen in the self-care dimension using the NDB dataset, the Clayton copula, displays a 
very different pattern of dependence compared to the Frank copula chosen in the EQG dataset. It exhibits 
asymmetric dependence on the tails with strong dependence at lower values and weak dependence at high 
values.  
 
There are significant statistical differences in the coefficients of the covariates and latent factor between EQ-5D-
3L and EQ-5D-5L in most dimensions. This highlights that the effect of moving from 3 levels to 5 levels is not 
just a uniform realignment of the response levels. The only exception to this in both datasets is in the 
anxiety/depression dimension and in the self-care dimension in the NDB dataset. 
Cost effectiveness results 
Table 3 and Figure 3 report headline results for all the case studies. In almost all cases, the switch from 3L to 
5L, causes a decrease in the incremental QALY gain from effective health technologies. This is true whether the 
estimation of 5L is based on EQG or NDB data.  
 
There are two exceptions.  In the WRAP study, we see that in the comparison of the 52-week programme 
(CP52) compared to the brief intervention, incremental QALYs increase, albeit very slightly, when using 5L 
(EQG) compared to 3L. Further investigation revealed that because utility was lower for intervention compared 
to control at 12 months, this caused the cumulative impact to lower total QALYs using 5L. The results of this 
case study were still consistent with the other case studies in that differences in utilities tend to be smaller using 
5L than with 3L.  
 
COUGAR 02 is the only other case study with an increase in incremental QALYs as a result of shifting from 3L 
to 5L. The increase is small but is apparent for both versions of 5L estimates. In COUGAR 2, mortality is a very 
substantial driver of cost effectiveness. Median overall survival in the DXL + ASC group was 5.2 months (95 
%CI 4.1–5.9) versus 3.6 months (3.3–4.4) in the ASC groupError! Bookmark not defined.. Here, the value of 
improved survival is greater because utility values are increased using 5L. It is worth noting that whilst the 
RAIN study also included patients with a substantial mortality rate (approximately 25% mortality within 6 
months) this was substantially lower than in COUGAR-02 (approximate 6-month mortality of 75% in the 
control group and 60% in the docetaxel armError! Bookmark not defined.) and did not outweigh the 
morbidity effect. 
 
The 5L instrument and tariff have the effect of shifting mean utility scores further up the utility scale towards 
full health, and compressing them into a smaller range. Thus, improvements in quality of life tend to be valued 
less using 5L than equivalent changes measured with 3L. 
 
In six of the nine reported comparisons, the incremental QALY gain is greater when measured using EQ5D-5L 
and the EQG dataset, compared to EQ5D-5L and the NDB dataset. One of the three remaining comparisons 
showed no difference. 
 
In those studies where the EQ5D-5L (EQG) lowered incremental QALYs, the impact ranged from a reduction of 
10.4% (CARDERA comparison of MTX to MTX plus PNS) to 75% (RAIN comparison of dedicated 
neurocritical care unit with combined neuro/general critical care unit). The comparable range when using 
mapping based on NDB data was 8% (CARDERA as before) to 87% (CACTUS).     
 
The impact of these changes on ICERs is also substantial in several cases. In CARDERA, the comparison of 
triple therapy compared to DMARD monotherapy changes from approximately £16k using EQ5D-3L to over 
£24k using EQ5D-5L (EQG data) and over £30k using EQ5D-5L (NDB data). CACTUS changes from a highly 
cost effective central estimate using EQ5D-3L (£3058) to one that is more borderline (£23022) using EQ5D-5L 
(NDB data). CVLPRIT changes from an ICER of £23k per QALY to in excess of £50k per QALY when using 
either estimate of 5L health utility. Other case studies demonstrate changes in cost effectiveness that may not 
span boundaries of typically cited cost-effectiveness thresholds but are, nevertheless, very substantial.   
 
CONCLUSIONS 
We have shown that EQ-5D-3L and 5L versions produce substantially different estimates of cost effectiveness 
in a series of case studies spanning different health conditions, severities and health technologies. Technologies 
that improve quality of life have those benefits valued more highly, in terms of health utility, when using the 3L 
instrument compared to 5L. This is because of the combined effect of the changed descriptive system and how 
individuals respond to it compared to 3L (which we demonstrated is not the same across each health dimension), 
and the changed valuation system. The result is that, in almost all cases, the incremental cost effectiveness ratio 
of a clinically effective technology rises (i.e. becomes less cost-effective) if the 5L instrument had been used in 
place of the 3L. Where the cost effectiveness of a technology is substantially driven by mortality rather than 
morbidity gains, the impact of shifting the 5L may lower ICERs.  
 
3L and 5L are not consistent with each other. There is not a simple proportional adjustment that can be made to 
reconcile differences between 3L and 5L. Changes do not impact equally across the distribution of health and 
therefore different technologies are affected to a different degree by the shift from one instrument to another.  
 
It is feasible to adjust 3L evidence to its 5L equivalent, as has been done in this paper. The validity of this 
approach is, in part, dependent on the data on which it is based. We have demonstrated this method in two 
separate datasets and shown that they give substantially different results. Further investigation of the reasons for 
these differences is required. In particular, the NDB includes only patients with rheumatoid disease and may not 
be generalizable to other populations. However, the design of the NDB questionnaires included much more 
separation between the completion of 3L and 5L and may, therefore, offer more independent observations than 
the EQG studies.  
 
There are a number of implications for policy in the light of these results. Given the differences between 3L and 
5L consistency in decision making will be difficult to achieve. Consideration must be given to the value of any 
cost-effectiveness threshold (or thresholds) or other means for making adjustments between the two instruments. 
Mapping can help achieve this, and the copula-based method is a sophisticated development of “response-
mapping” that obtains consistent and accurate results. 5L is increasingly being used in studies of clinical 
effectiveness, but this is unlikely to entirely replace existing evidence using 3L that will remain of relevance to 
many economic evaluations for many years to come.  
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TABLES:  
Table 1: Descriptive statistics in the EQG and NDB estimation samples 
 EQG sample NDB sample 
Mean 
[95%  confidence Interval] 
51.23 
[50.57, 51.89] 
63.32 
[62.99, 63.65] 
Median 
[95%  confidence Interval] 
54 
[54, 56] 
64.13 
[63.78, 64.46] 
Standard Deviation 20.11 12.31 
Minimum 13 16.66 
Maximum 99 95.20 
Proportion female 0.53 0.81 
 EQ-5D-3L EQ-5D-5L EQ-5D-3L EQ-5D-5L 
Mean 
[95%  confidence Interval] 
0.628 
[0.617, 0.639] 
0.712 
[0.703, 0.722] 
0.681 
[0.674, 0.688] 
0.779 
[0.773, 0.784] 
Median 
[95%  confidence Interval] 
0.691 
[0.691, 0.725] 
0.802 
[0.792, 0.816] 
0.725 
[0.725, 0.727] 
0.823 
[0.817, 0.829] 
Standard Deviation 0.333 0.278 0.254 0.191 
Minimum -0.594 -0.281 -.594 -0.226 
Maximum 1 1 1 1 
     
Number of health states 
[percentage out of possible 
health states] 
123 
[50.62] 
660 
[21.12] 
86 
[35.39] 
524 
[16.77] 
 
Table 2: Summary of final model results 
 EQG NDB 
Log-likelihood -23891.83 -33621.04 
Number of parameters 78 68 
Observations 3551 5205 
Type of mixture in copula Single mixture Single mixture 
Dimension Specific   
Mobility   
Copula Frank Gaussian 
Equality of coefficients (covariates) 7.12* 11.86*** 
Equality of coefficients (latent factor) 8.37*** 10.64*** 
Equality of coefficients (covariates & factor) 12.19** 26.49*** 
Self-care   
Copula Frank Clayton 
Equality of coefficients (covariates) 8.53** 1.21 
Equality of coefficients (latent factor) 3.68* 0.09 
Equality of coefficients (covariates & factor) 9.39* 1.35 
Usual activities   
Copula Frank Gaussian 
Equality of coefficients (covariates) 3.29 0.67 
Equality of coefficients (latent factor) 5.62** 8.24*** 
Equality of coefficients (covariates & factor) 0.04** 9.11** 
Pain/discomfort   
Copula Frank Gaussian 
Equality of coefficients (covariates) 0.57 34.36*** 
Equality of coefficients (latent factor) 9.36*** 19.99*** 
Equality of coefficients (covariates & factor) 11.95** 50.74*** 
Anxiety/depression   
Copula Frank Frank 
Equality of coefficients (covariates) 5.60 4.94* 
Equality of coefficients (latent factor) 1.23 1.94 
Equality of coefficients (covariates & factor) 7.08 6.19 
Statistical significance: * = 10%, ** = 5%, *** = 1% 
 
Table 3: Incremental QALYs and ICERs for 3L, 5L (EQG) and 5L (NDB) across all case studies 
 
Inc QALYs ICER 
 
3L 
5L 
EuroQoL % change 5L NDB % change 3L 
5L 
EuroQoL % change 5L NDB % change 
CARDERA 1 0.145 0.113 21.8% 0.111 23.2% 4648 5940 27.8% 6054 30.3% 
CARDERA 2  0.084 0.075 10.4% 0.077 8.0% 13666 15252 11.6% 14846 8.6% 
CARDERA 3  0.082 0.054 33.5% 0.043 47.6% 15929 23940 50.3% 30418 91.0% 
Cactus 0.150 0.050 66.7% 0.020 86.7% 3058 9481 210.0% 23022 652.8% 
Rain a 0.020 0.005 75.0% 0.003 85.0% 184700 738800 300.0% 1231333 566.7% 
Rain b 0.051 0.021 58.8% 0.021 58.8% 294137 714333 142.9% 714333 142.9% 
Improve 0.052 0.046 11.5% 0.042 19.2% -44617 -48113 7.8% -54742 22.7% 
Cougar 2 0.115 0.119 -3.5% 0.118 -2.6% 27180 26434 -2.7% 26484 -2.6% 
Arctic 0.059 0.043 27.1% 0.046 22.0% 112193 162774 45.1% 152130 35.6% 
Sharpish 0.000 -0.003    -0.003             
WRAP - CP12 0.062 0.047 23.7% 0.039 36.2% 1812 2373 31.0% 2840 56.7% 
WRAP - CP52 0.044 0.044 0.0% 0.036 19.0% 4305 4312 0.2% 5316 23.5% 
CvLPRIT 0.020 0.009 55.5% 0.009 56.9 23208 51614 122.4% 53908 132.3% 
CARDERA 1 = MTX vs MTX + CS, CARDERA 2 = MTX vs MTX + PNS, CARDERA 3 = MTX + CS + PNS vs MTX 
 
 
 FIGURES 
Figure 1: Response histograms for EQ-5D-3L and EQ-5D-5L in the EQG dataset and the NDB dataset 
EQG dataset (n=3551) NDB dataset (n=5205) 
  
 
  
Figure 2: Smoothed empirical distribution functions of EQ-5D-3L and EQ-5D-5L in the EQG and NDB 
datasets. 
EQG dataset (n=3551) 
 
NDB dataset (n=5205) 
 
 
Figure 3: Histogram of incremental QALYs by 3L, 5L (EQG) and 5L (NDB) for all case studies 
 
CARDERA 1 = MTX vs MTX + CS, CARDERA 2 = MTX vs MTX + PNS, CARDERA 3 = MTX + CS + PNS vs MTX 
 
 
 
